Latest Breaking News On - Curasightas curasight - Page 1 : comparemela.com

Curasight resolves on a rights issue of up to DKK 51.2 million to accelerate its therapeutic strategy

COPENHAGEN, Denmark, Feb. 13, 2024 /PRNewswire/  Curasight A/S Curasight or the Company – has today resolved on a new issue of shares with preferential rights for the Company s existing.

Curasight A/S reports positive preclinical results with uTREAT[®] in lung cancer (NSCLC)

Preclinical studies show uTREAT® effective in treating non-small cell lung cancer Data follows recent announcement of positive preclinical results within glioblastoma and supports hypothesis.

Positive results from the Phase II study of uTRACE in brain cancer presented at the World Molecular Imaging Congress (WMIC) 2023 in Prague

Curasight A/S ("Curasight" or the "Company" - TICKER: CURAS) announces today that the previously announced results from the investigator-initiated phase II study using uPAR-PET (uTRACE®) in primary brain cancer have been presented in an oral presentation at the World Molecular Imaging Congress (WMIC) 2023 in .

Positive results in uPAR-PET/MR Phase II study in brain cancer: Curasight

Curasight to present at HC Andersen Capital and Økonomisk Ugebrev

Copenhagen, Denmark, 26 May 2023 - Curasight A/S hereby announces that CEO Ulrich Krasilnikoff and CSO professor Andreas Kjær will present the company s Interim Report Q1 2023 at HC. | May 26, 2023